Anita H. Clayton

Anita H. Clayton's AcademicInfluence.com Rankings

Anita H. Clayton

Biology

#13809

World Rank

#17391

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Anita H. Clayton Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Anita H. Clayton is the Chair of Psychiatry and Neurobehavioral Sciences and the David C. Wilson Professor of Psychiatry and Neurobehavioral Sciences in the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia School of Medicine. From 2005 to 2007, she was the President of the International Society for the Study of Women's Sexual Health .

(See a Problem?)

Anita H. Clayton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prevalence of sexual dysfunction among newer antidepressants. (2002) (521)
Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. (2008) (491)
The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. (1997) (313)
Positron-Emission Tomography and Personality Disorders (1994) (269)
15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. (2005) (237)
Reliability and Construct Validity of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) (2006) (186)
A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. (2004) (184)
Bupropion Sustained Release for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women (2004) (179)
Clinical evaluation and management strategy for sexual dysfunction in men and women. (2004) (175)
The blood brain barrier and the role of cytokines in neuropsychiatry. (2009) (167)
Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). (2009) (153)
The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women (2018) (151)
Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review (2017) (147)
Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. (2006) (131)
Summit on medical school education in sexual health: report of an expert consultation. (2013) (126)
Reliability and Validity of the Sexual Interest and Desire Inventory–Female (SIDI-F), a Scale Designed to Measure Severity of Female Hypoactive Sexual Desire Disorder (2006) (126)
ORIGINAL RESEARCH—PSYCHOLOGY: Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder (2007) (122)
Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part II. (2016) (119)
Continuing Medical Education: Sexual Medicine Education: Review and Commentary (CME) (2007) (118)
Burden of phase-specific sexual dysfunction with SSRIs. (2006) (102)
Antidepressants and Sexual Dysfunction: Mechanisms and Clinical Implications (2014) (99)
Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). (1997) (97)
Distressing sexual problems in United States women revisited: prevalence after accounting for depression. (2009) (96)
Sexual dysfunction associated with major depressive disorder and antidepressant treatment (2014) (95)
The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder (2015) (94)
Serotonin 2A −1438 G/A and G-Protein Beta3 Subunit C825T Polymorphisms in Patients with Depression and SSRI-Associated Sexual Side-Effects (2006) (93)
A Double-blind Comparison Between Bupropion XL and Venlafaxine XR: Sexual Functioning, Antidepressant Efficacy, and Tolerability (2006) (90)
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. (2007) (90)
Proposal for changes in diagnostic criteria for sexual dysfunctions. (2007) (89)
Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder (2003) (83)
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. (2015) (80)
Female sexual dysfunction related to depression and antidepressant medications. (2002) (80)
Epidemiology and neurobiology of female sexual dysfunction. (2007) (78)
The pathophysiology of hypoactive sexual desire disorder in women (2010) (78)
Sexual function and dysfunction in women. (2003) (76)
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. (2001) (75)
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial (2016) (75)
The impact of physical illness on sexual dysfunction. (2008) (72)
Depression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women. (2010) (72)
Sexual well-being after menopause: An International Menopause Society White Paper (2018) (71)
Symptoms Related to the Menstrual Cycle: Diagnosis, Prevalence, and Treatment (2008) (69)
Sexual medicine education: review and commentary. (2007) (68)
Issues for DSM-V: sexual dysfunction, disorder, or variation along normal distribution: toward rethinking DSM criteria of sexual dysfunctions. (2007) (67)
Recognition and assessment of sexual dysfunction associated with depression. (2001) (63)
Psychological Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective. (2015) (63)
Women's Mental Health: A Comprehensive Textbook (2002) (60)
An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder (2009) (58)
Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 1. For women with incomplete loss of desire or sexual receptivity. (2012) (58)
The effect of vilazodone on sexual function during the treatment of major depressive disorder. (2013) (56)
Comparison of androgens in women with hypoactive sexual desire disorder: those on combined oral contraceptives (COCs) vs. those not on COCs. (2006) (55)
Sexual Dysfunction Due to Psychotropic Medications. (2016) (55)
Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. (2008) (54)
The impact of mental illness and psychotropic medications on sexual functioning: the evidence and management. (2009) (54)
Major depressive disorder, antidepressants, and sexual dysfunction. (2006) (54)
Sexual function in women with polycystic ovary syndrome. (2011) (53)
ORIGINAL RESEARCH—WOMEN's SEXUAL DYSFUNCTIONSORIGINAL RESEARCH—WOMEN's SEXUAL DYSFUNCTIONS: The Sexual Interest and Desire Inventory—Female (SIDI‐F): Item Response Analyses of Data from Women Diagnosed with Hypoactive Sexual Desire Disorder (2005) (52)
Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder (2010) (50)
Should Sexual Desire and Arousal Disorders in Women Be Merged? (2011) (50)
Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. (2006) (47)
Female Sexual Interest/Arousal Disorder: A Diagnosis Out of Thin Air (2014) (45)
Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment. (2010) (45)
Physician attitudes regarding hypoactive sexual desire disorder in a primary care clinic: a pilot study. (2008) (44)
Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. (2013) (43)
Assessment of sexual functioning during the menstrual cycle. (1999) (42)
Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. (1995) (41)
Menopausal status in breast cancer patients with past chemotherapy determines long-term hypoactive sexual desire disorder. (2011) (41)
Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis (2015) (41)
Validation of the sexual interest and desire inventory-female in hypoactive sexual desire disorder. (2010) (41)
Postpartum depression, urge urinary incontinence, and overactive bladder syndrome: is there an association? (2007) (41)
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (2019) (40)
Chronic episodic disorders in women. (2003) (40)
Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. (2014) (39)
Female Sexual Dysfunction. (2019) (38)
Transient SIADH associated with fluoxetine. (1990) (38)
Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 2. For women with loss of subjective sexual arousal. (2012) (37)
Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies (2006) (36)
Evaluation and Management of Hypoactive Sexual Desire Disorder (2018) (34)
Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial (2015) (32)
Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part III. (2019) (32)
Female sexual dysfunction. (2009) (32)
The Sexual Interest and Desire Inventory-Female (SIDI-F): item response analyses of data from women diagnosed with hypoactive sexual desire disorder. (2005) (31)
Serotonergic Activation Rescues Reproductive Function in Fasted Mice: Does Serotonin Mediate the Metabolic Effects of Leptin on Reproduction?1 (2002) (30)
I. Survey of Literature (1942) (29)
Female Sexual Dysfunction. (2010) (29)
Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. (2007) (28)
Medical students' perceptions of sexual health issues prior to a curriculum enhancement (2003) (27)
Depression in Premenopausal Women With HSDD: Baseline Findings From the HSDD Registry for Women (2012) (27)
Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender–age interactions (2007) (27)
Changes in Sexual Functioning Questionnaire (2010) (27)
Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder (2010) (25)
Association of major depression with sexual dysfunction in men. (2013) (25)
The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD. (2020) (24)
Validity of the Decreased Sexual Desire Screener for Diagnosing Hypoactive Sexual Desire Disorder (2013) (24)
An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. (2013) (23)
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. (2019) (23)
Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? (2007) (23)
Flibanserin: From Bench to Bedside. (2017) (22)
Cutoff score of the sexual interest and desire inventory-female for diagnosis of hypoactive sexual desire disorder. (2010) (22)
Fluoxetine and nortriptyline combination therapy. (1989) (21)
Assessing the onset of antidepressant-induced sexual dysfunction using interactive voice response technology. (2007) (20)
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder (2019) (20)
Exploratory study of premenstrual symptoms and serotonin variability (2005) (20)
Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine. (1995) (20)
Antidepressant-induced tardive dyskinesia: review and case report. (1995) (19)
Assessment of Sexual Desire for Clinical Trials of Women With Hypoactive Sexual Desire Disorder: Measures, Desire-Related Behavior, and Assessment of Clinical Significance. (2018) (18)
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study (2014) (18)
Blood brain barrier: the role of calcium homeostasis. (2007) (18)
Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study (2016) (18)
Recognition of depression among women presenting with menopausal symptoms (2008) (17)
Clinical role of brexpiprazole in depression and schizophrenia (2017) (16)
Sexual functioning of Latino women seeking outpatient gynecologic care. (2009) (15)
A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. (2015) (15)
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram (2019) (15)
Female sexual dysfunctions: what controversy? (2006) (15)
Female sexual dysfunction. (2010) (15)
Bremelanotide for Hypoactive Sexual Desire Disorder: Analyses From a Phase 2B Dose-Ranging Study (2014) (14)
Sertraline in the treatment of panic disorder. (2009) (14)
Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. (2017) (14)
Expert opinion on existing and developing drugs to treat female sexual dysfunction (2018) (14)
Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder (2014) (14)
The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. (2012) (14)
Sexual Function Across Aging (2016) (14)
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. (2019) (14)
Evaluation of safety for flibanserin (2019) (13)
Treating depression complicated by comorbid medical illness or anxiety. (2007) (13)
Etiology of Female Sexual Dysfunction (2013) (13)
Textbook of Female Sexual Function and Dysfunction. Diagnosis and Treatment (2022) (12)
Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies (2016) (12)
Blood Brain Barrier: The Role of GAD Antibodies in Psychiatry. (2007) (12)
Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled Trial. (2018) (11)
A roadmap to key pharmacologic principles in using antipsychotics. (2007) (11)
Geriatric Depression Scale vs. Hamilton Rating Scale for Depression in a Sample of Anxiety Patients (1997) (11)
Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program (2014) (11)
Glutamic acid decarboxylase (GAD) antibodies in tardive dyskinesia (TD) as compared to patients with schizophrenia without TD and normal controls (2008) (10)
Sex Differences in the Treatment of Sexual Dysfunction (2018) (9)
Blood brain barrier: the role of pyridoxine. (2007) (9)
What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder (2016) (9)
Safety of Flibanserin in Women Treated With Antidepressants: A Randomized, Placebo-Controlled Study. (2018) (9)
Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram (2011) (8)
Further commentary on DSM-5 FSIAD diagnosis. (2015) (8)
Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women. (2019) (8)
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (2021) (7)
Obstructive sleep apnea, hypoxia, and metabolic syndrome in psychiatric and nonpsychiatric settings. (2008) (7)
Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis (2015) (7)
Concerns in depression treatment : Sexual dysfunction and weight gain (2007) (7)
The blood brain barrier and the role of ratiometric molecular analysis in schizophrenia. (2010) (7)
Effects of Timing of Flibanserin Administration Relative to Alcohol Intake in Healthy Premenopausal Women: A Randomized, Double-Blind, Crossover Study. (2019) (7)
Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin (2022) (7)
Increase in white blood cell count and serum sodium level following the addition of lithium to carbamazephine treatment among three chronically psychotic male patients with disturbed affective states (1986) (7)
Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects (2019) (7)
Effect Size in Efficacy Trials of Women With Decreased Sexual Desire. (2018) (7)
Effect of Brexpiprazole on Prolactin and Sexual Functioning (2020) (6)
The Impact of Antidepressant-Associated Sexual Dysfunction on Treatment Adherence in Patients with Major Depressive Disorder (2013) (6)
Pathophysiology and Medical Management of Hypoactive Sexual Desire Disorder (2018) (6)
Addressing sexual concerns of female breast cancer survivors and partners: a qualitative study of survivors, partners, and oncology providers about Internet intervention preferences (2021) (6)
Decreased Sexual Desire Screener (2010) (5)
Research report Burden of phase-specific sexual dysfunction with SSRIs B (2006) (5)
A possible association of Ganser's syndrome and major depression. (1990) (5)
Fetishism and clomipramine. (1993) (5)
GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus. (2011) (5)
Failure of a Meta-analysis: A Commentary on Glen Spielmans’s “Re-Analyzing Phase III Bremelanotide Trials for ‘Hypoactive Sexual Desire Disorder in Women’” (2021) (5)
Models vs. Realities in Female Sexual Dysfunction. (2015) (5)
Effects of Alcohol Administered With Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study. (2019) (5)
Combination therapy in fibromyalgia. (2006) (5)
Evaluation of Flibanserin Safety: Comparison with Other Serotonergic Medications. (2019) (5)
Medical Students’ Attitudes Toward Sexual Contact With Patients and Supervisors (1991) (4)
Thoughts on the U.S. Food and Drug Administration (FDA) Draft Guidance on Low Sexual Desire and Arousal. (2017) (4)
The other side: failure in fair and balanced reporting. (2005) (4)
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder (2022) (4)
Vulnerability to depression and cardiometabolic risk associated with early ovarian disruption. (2013) (4)
Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate (2013) (4)
Response and Rebuttal to Editorial Comment on "Psychological Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective". (2015) (4)
Efficacy of Bremelanotide for HSDD in Women: RECONNECT Open-Label Extension Phase Results [8Q] (2018) (4)
Understanding antidepressant mechanism of action and its effect on efficacy and safety. (2012) (4)
Blood-Brain Barrier: COVID-19, Pandemics, and Cytokine Norms. (2021) (4)
Thermoregulation and the role of calcium signalling in neurotransmission. (2008) (4)
Role of cholinergic system and calcium synchronization in schizophrenia. (2009) (4)
The Design and Evaluation of a Group Research Experience During Psychiatric Residency Training (2001) (4)
Instruments for Screening, Diagnosis, and Management of Patients with Generalized Acquired Hypoactive Sexual Desire Disorder. (2020) (3)
T09-P-05 Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD) (2008) (3)
014 The Investigational Drug Bremelanotide for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses from the RECONNECT Studies (2018) (3)
O181 Baseline characteristics of patients enrolled in three phase III North American trials of flibanserin in premenopausal women with hypoactive sexual desire disorder (2009) (3)
Including partners in discussions of sexual side effects from breast cancer: a qualitative study of survivors, partners, and providers (2022) (3)
017 Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD) in the RECONNECT Study: Efficacy Analyses in Study Completers and Responders (2017) (3)
P.2.f.022 Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction (2014) (3)
P-10-17 Double-blind flexible dose study of sertraline and placebo in patients with panic disorder (1996) (3)
Is Flibanserin Meaningfully Superior to Placebo? (2017) (3)
Placental Barrier and Autism Spectrum Disorders: The Roles of Prolactin and Dopamine in the Developing Fetal Brain-Part II. (2019) (2)
Onset of obstructive sleep apnea after initiation of psychotropic agents. (2007) (2)
Hypoactive Sexual Desire Disorder: Separating Fact from Fiction (2015) (2)
Biochemical evidence of the placebo effect during the treatment of menstrual migraines. (2005) (2)
Gender differences in clinical psychopharmacology. (2005) (2)
Response to Balon’s Commentary: Is Basson’s Model of Sexual Response Relevant? (2021) (2)
221 Bremelanotide: A Review of its Neurobiology and Treatment Efficacy for HSDD (2017) (2)
Lumping, Splitting, and Treating: Therapies Are Needed for Women With Overlapping Sexual Dysfunctions. (2019) (2)
P0031 - Pooled analysis of the safety and tolerability of desvenlafaxine Succinate compared with placebo in the treatment of major depressive disorder (2008) (2)
A Brief Version of the Sexual Interest and Desire Inventory-Female With 4 Core Items. (2018) (2)
JSM HIGHLIGHTSSurvey of Literature (2006) (2)
222 The Neurobiology and Efficacy of Bremelanotide in HSDD (2017) (2)
Current Literature Review: Survey of Literature (2011) (2)
P.1.g.042 Efficacy of bremelanotide in The RECONNECT Studies (2017) (2)
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. (2022) (2)
Placental Barrier and Autism Spectrum Disorders: The Role of Prolactin and Dopamine on the Developing Fetal Brain. (2015) (2)
Focus on Women's Mental Health (2011) (2)
Bremelanotide for Hypoactive Sexual Desire Disorder: Contraceptive Subgroups Efficacy Analysis [15OP] (2019) (2)
Insomnia and attention deficit hyperactivity disorder in pediatrics: a checklist for parents. (2013) (1)
Medical student curricula/sexual medical education (2005) (1)
SURVEY OF LITERATURESURVEY OF LITERATURE (2005) (1)
007 Medical Student Attitudes, Knowledge, and Comfort Level Related to Patients’ Sexual Health (2016) (1)
GABA-A Receptor Positive Allosteric Modulators as a Novel Approach to Treating Depression: A Review of Available Data (2021) (1)
215 Bremelanotide for Hypoactive Sexual Desire Disorder: Age and Weight Subgroup Efficacy Analyses (RECONNECT Studies) (2019) (1)
Reboxetine and sexual side effects (2001) (1)
016 Changes in Arousal and Desire in the Bremelanotide RECONNECT Study (2017) (1)
Combination therapy in the treatment of major depressive disorder complicated by fibromyalgia and menopause. (2002) (1)
193 Bremelanotide for Hypoactive Sexual Desire Disorder: Contraceptive Subgroups Efficacy Analysis (2020) (1)
Potential Role of Androgens in the Treatment of Hypoactive Sexual Desire in Women (2005) (1)
Standards in Studies of Psychotherapy and Pharmacotherapy Interventions for HSDD (2017) (1)
Obstructive sleep apnea: Screenings in primary, secondary and tertiary care settings (2013) (1)
Treatment of Hypoactive Sexual Desire Disorder Among Women: General Considerations and Pharmacological Options. (2021) (1)
Flibanserin: More Than Just a “Pink Viagra” (2015) (1)
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study (2014) (1)
Sexual Interest and Desire Inventory—Female (2017) (1)
Affective disorder following use of phenylpropanolamine. (1990) (1)
Women and dementia (2005) (1)
PrefaceWomen's mental health (2003) (1)
Single Nucleotide Polymorphisms and the Central Nervous System: Potential Biomarkers in Identifying Suicide Risk. (2017) (1)
007 Bremelanotide (BMT) for hypoactive sexual desire disorder (HSDD): efficacy analyses from the RECONNECT studies (2018) (1)
Male sexual dysfunction: Current diagnosis and treatment. (2012) (1)
Quantitative and Qualitative Research in HSDD: The Difference Between Testing Theory and Generating New Theories (2017) (1)
Weight issues in schizophrenia (2006) (1)
Bremelanotide for Hypoactive Sexual Desire Disorder: Age and Weight Subgroup Efficacy Analyses [1Q] (2018) (1)
Efficacy of Bremelanotide Across Hypoactive Sexual Desire Disorder Duration Subgroups [15M] (2019) (1)
Women's Mental Health (2003) (1)
084 Improvements in Female Sexual Function Index (FSFI) Domains Over Time after Flibanserin Treatment in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) (2020) (1)
144 Safety of Flibanserin in Women With Hypoactive Sexual Desire Disorder Taking Antidepressant Medications (2019) (0)
Complementary and alternative medicine (2005) (0)
194 Effect Size of Bremelanotide Treatment in the Phase 3 RECONNECT Studies (2020) (0)
139 Effects of Alcohol Administered With Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose, Seven-Way Crossover Study (2019) (0)
029 Bremelanotide for Hypoactive Sexual Desire Disorders in the RECONNECT Studies: Analysis of Baseline Free Testosterone Level Quartile Subgroups (2019) (0)
038 Effect Size of Bremelanotide Treatment in the Phase 3 RECONNECT Studies (2020) (0)
Hypoactive Sexual Desire Disorder (2018) (0)
Accidental Flibanserin Ingestion in Children Causing Acute Respiratory and Central Nervous System Depression: What Health Care Professionals Need to Know. (2022) (0)
SAGE-217 in Major Depressive Disorder: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial (705) (2020) (0)
011 Correlation Between Validated Instruments Used in the RECONNECT Studies (2020) (0)
021 Flibanserin in Premenopausal Women With Hypoactive Sexual Desire Disorder: Pooled Analysis of Safety From Phase 3, Placebo-Controlled Studies (2018) (0)
Corrigendum (2019) (0)
Women's Mental Health: Progress and Realities. (2017) (0)
Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial. (2023) (0)
Women's Mental Health: Progress and Realities. (2019) (0)
Safety of Flibanserin in Women With Hypoactive Sexual Desire Disorder Taking Antidepressant Medications [1D] (2018) (0)
001 Composite Endpoints for Clinical Trials of Women with HSDD: Content, Responder Values, and Remitter Cutoffs (2018) (0)
MALE AND FEMALE SEXUAL FUNCTION AND DYSFUNCTION (2016) (0)
CNS volume 21 issue 5 Cover and Front matter (2016) (0)
Overview of the Rapid Antidepressant Effects Observed in the Zuranolone Clinical Development Program [A164] (2022) (0)
Sexuality during Menopause: Deconstructing the Myths (2009) (0)
Marcel D. Waldinger, MD, PhD: January 17, 1955 - May 1, 2019. (2019) (0)
Response to Commentary by Spielmans (2022) (0)
Safety Profile of Bremelanotide Across the Clinical Development Program. (2022) (0)
Osteoporosis, Coronary Heart Disease, and Breast Cancer Risk Tools for Menopausal Women Considering Hormone Therapies (2001) (0)
Medical Students' Attitudes toward Substance Abuse (1995) (0)
140 The Impact of the Timing of Alcohol Consumption on the Safety and Tolerability of Flibanserin (2019) (0)
2.53 Sexual Functioning in Adolescents With Major Depression: A Prospective Study (2017) (0)
Female Sexual Interest/Arousal Disorder: A Diagnosis Out of Thin Air (2014) (0)
076 Lumping, Splitting, and Treating: Therapies are Needed for Women with Overlapping Sexual Dysfunctions (2019) (0)
An Innovative Model of Behavior Management to Address Behavioral Emergencies in the Acute Medical Inpatient Setting: Pilot Data (2021) (0)
Reboxetine and sexual side effects (2002) (0)
006 Bremelanotide for Hypoactive Sexual Desire Disorder: Integrated Subgroup Analysis According to FSFI Total Score at Screening (2018) (0)
Sexual Energy Scale (SES): A Valid Assessment of Sexual Dysfunction in a Clinical Setting (2000) (0)
Understanding and treating women’s sexual dysfunction: Where are we now? (2012) (0)
Changes in Sexual Functioning Questionnaire--Short Form (2018) (0)
012 Bremelanotide Treatment Provided Clinically Meaningful Benefits in Premenopausal Women With Hypoactive Sexual Desire Disorder (2020) (0)
Weight issues with depression and antidepressant medications (2005) (0)
Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management (2022) (0)
Decision-making About Estrogen Therapy: P-22. (1999) (0)
S.34.02 Effects of antidepressants on sexual function and satisfaction – implications for drug development (2017) (0)
Depression and Sexual Life (2016) (0)
P.577 Elements of desire questionnaire assessment of bremelanotide efficacy for hypoactive sexual desire disorder in the reconnect studies (2019) (0)
O-67:Validation of the “Decreased Sexual Desire Screener” (DSDS): A brief diagnostic instrument for generalized, acquired hypoactive sexual desire disorder in women (2006) (0)
Information Tools for Menopausal Women Considering Hormone Therapies (1999) (0)
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD. (2023) (0)
103 The Effect of Evening Alcohol Consumption and Bedtime Administration of Flibanserin on the Safety of Flibanserin (2019) (0)
P.2.b.005 Effects of vilazodone on sexual dysfunction in major depressive disorder: randomised, double-blind trial with placebo and active controls (2014) (0)
Recent advances in the treatment of depression in the presence of physical symptoms. (2006) (0)
P.305 The GABAA receptor positive allosteric modulator zuranolone in major depressive disorder: a double-blind, randomized, placebo-controlled phase 3 trial (2020) (0)
Pharmacotherapy for Sexual Dysfunction in Women (2022) (0)
P.2.c.007 Comparison of bupropion extended release and venlafaxine extended release for the treatment of depression: a double-blind, multicentre trial (2006) (0)
From the Guest Editors T (2012) (0)
Preface Women's mental health (2003) (0)
Lurasidone treatment of major depression with mixed features: Effect on sexual function (2016) (0)
Contents (2017) (0)
Major Depressive Disorder, Suicides, and the Role of Dimensional Psychiatry for Triaging in Primary Care Settings: A Case Series Retroanalysis. (2022) (0)
Preface: Advances in women's mental health. (2010) (0)
Outcomes in breast cancer : Disease and treatment effects on mood and sexual functioning (2005) (0)
Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2023) (0)
466 Sexual functioning in people taking antidepressants and healthy volunteers in Japan: A cross sectional online survey (2018) (0)
138 Bremelanotide for Hypoactive Sexual Desire Disorder in the RECONNECT Study: Analysis of Co-Primary Endpoints According to Baseline FSFI Total Scores (2019) (0)
Economic Outcomes with Adjunctive Cariprazine and Other Atypical Antipsychotics in Patients with Major Depressive Disorder (2023) (0)
081 Lorexys Phase 2a Results: Patient’s Global Impression of Change (PGIC) (2019) (0)
Placental barrier and autism spectrum disorders (2015) (0)
020 Bremelanotide Treatment Provided Clinically Meaningful Benefits in Premenopausal Women With Hypoactive Sexual Desire Disorder (2020) (0)
064 Hemodynamic and Pharmacokinetic Interactions of Intranasal Bremelanotide and Ethanol in a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Three-Period, Three-Way Crossover Study (2017) (0)
102 The Impact of the Timing of Alcohol Consumption on the Safety and Tolerability of Flibanserin (2019) (0)
PD54-01 SAFETY OF FLIBANSERIN IN WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER TAKING ANTIDEPRESSANT MEDICATIONS (2018) (0)
015 Efficacy of Flibanserin by Duration of Hypoactive Sexual Desire Disorder in Premenopausal Women (2018) (0)
Patient Satisfaction with Psychiatric Treatment of Menopausal Women in a Multidisciplinary Women's Midlife Center (1998) (0)
Mood effects of hormones in women (2005) (0)

This paper list is powered by the following services:

Other Resources About Anita H. Clayton

en.wikipedia.org

What Schools Are Affiliated With Anita H. Clayton?

Anita H. Clayton is affiliated with the following schools:

University of Virginia